Rhode Island Hospital; Alpert Medical School of Brown University; New York-Presbyterian Hospital; Weill Cornell Medical College, Cornell University.
Massachusetts General Hospital; Harvard Medical School.
J Affect Disord. 2021 May 15;287:34-40. doi: 10.1016/j.jad.2021.03.011. Epub 2021 Mar 11.
Research on predictors of treatment outcome in body dysmorphic disorder, a common and severe disorder, is very limited, and no prior studies have examined moderators of outcome. Because treatment is often but not always efficacious, it is important to identify who is more likely to benefit. We examined predictors and moderators of improvement with therapist-delivered cognitive-behavioral therapy versus supportive psychotherapy in the only study of these treatments for body dysmorphic disorder. This report presents secondary analyses from a study whose primary findings have previously been published (Wilhelm et al., 2019).
Participants (N=120) with DSM-IV body dysmorphic disorder were randomized to therapist-delivered weekly cognitive-behavioral therapy or supportive therapy for 24 weeks. Using reliable and valid measures, we tested baseline body dysmorphic disorder severity, insight/delusionality, and depression severity as predictors and moderators of overall and treatment modality-specific symptom change. We explored additional variables as predictors and moderators of outcome.
Greater treatment credibility (p=0.02) and presence of obsessive-compulsive personality disorder (p=0.03) predicted greater improvement. Serotonin-reuptake inhibitor treatment at baseline (unchanged during the study) (p=0.01) predicted less improvement. No other variables predicted or moderated outcome (all p>0.05).
The study was not powered a priori to detect predictor or moderation effects, which limited our ability to detect them unless they were strong.
Because greater treatment credibility predicted better outcomes, fostering credibility during therapy may maximize gains. Improvement was not impeded by more severe body dysmorphic disorder, depressive symptoms, or poorer insight. No variables moderated treatment-specific improvement.
躯体型障碍是一种常见且严重的障碍,目前对其治疗结果预测因素的研究非常有限,也没有研究检验过治疗结果的调节因素。因为治疗通常(但并非总是)有效,所以确定谁更有可能受益是很重要的。我们在针对躯体型障碍的这两种治疗方法(即,治疗师提供的认知行为疗法与支持性心理疗法)的唯一研究中,检验了改善的预测因素和调节因素。本报告介绍了先前已发表的一项研究(Wilhelm 等人,2019 年)的二次分析结果。
120 名符合 DSM-IV 躯体型障碍的参与者被随机分配到治疗师提供的每周认知行为疗法或支持性疗法,为期 24 周。我们使用可靠和有效的测量工具,检验了基线躯体型障碍严重程度、洞察力/妄想程度和抑郁严重程度作为整体和治疗方式特异性症状变化的预测因素和调节因素。我们还探索了其他变量作为预测因素和调节因素。
更高的治疗可信度(p=0.02)和存在强迫型人格障碍(p=0.03)预测了更大的改善。基线时接受了选择性 5-羟色胺再摄取抑制剂治疗(在研究期间未改变)(p=0.01)预测了改善较少。其他变量均未预测或调节结果(均 p>0.05)。
该研究事先没有确定预测因素或调节效应的能力,这限制了我们检测它们的能力,除非它们很强烈。
因为更高的治疗可信度预测了更好的结果,所以在治疗过程中培养可信度可能会最大限度地提高收益。更严重的躯体型障碍、抑郁症状或较差的洞察力并没有阻碍改善。没有变量调节特定治疗的改善。